Galectin Therapeutics (GALT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Galectin Therapeutics (GALT) is Neutral.

The composite score behind that read is -0.10, weighing +0.09 of bullish evidence against -0.25 bearish.

Galectin Therapeutics last closed at $3.64, +0.55% on the session.

Against the IVW growth benchmark the position is +1.78% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

2 graded predictions for GALT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Galectin Therapeutics in the 82nd percentile on return on equity, where 100 is best.

Galectin Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $365.08M.

StockMap tracks Galectin Therapeutics as the 199th largest of the 380 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 304 Neutral, 65 Moderate Underperform and 11 Moderate Outperform.

On that composite Galectin Therapeutics ranks 202nd of 380 in the group, against a group median of -0.10.